LP-003 (Tianchen Biomedical)

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameLP-003 (Tianchen Biomedical)
Drug Alias NameLP-003
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAnti-IgE
TargetsImmunoglobulin E
Therapy Area/IndicationsAllergic asthmaChronic rhinosinusitis with nasal polyps (CRSwNP)Food Hypersensitivity +[13
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesLongbio Pharma (Suzhou) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Inactive CompaniesN/A
Active IndicationsAllergic asthmaChronic rhinosinusitis with nasal polyps (CRSwNP)Food Hypersensitivity +[12
Inactive IndicationsRespiratory Tract Diseases

Other Information

ATC CodeN/A
Related LinksN/A